A Single-center, Double-blind Placebo-controlled Parallel Group Phase II Study of the Efficacy and Safety of Rilonacept in Subjects With Cold Contact Urticaria (CCU)
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 13 Mar 2018
At a glance
- Drugs Rilonacept (Primary)
- Indications Urticaria
- Focus Therapeutic Use
- Acronyms Cures
- 14 Dec 2017 Planned primary completion date changed from 1 Dec 2017 to 1 Feb 2018.
- 14 Dec 2017 Status changed from recruiting to active, no longer recruiting.
- 05 Jan 2017 Planned End Date changed from 1 Apr 2017 to 1 Apr 2018.